report by BlackRock
Results for ""
Human Capital
The Active Share Podcast: What’s Culture Got to Do With It?
This piece is approved to use with clients.
As it turns out, culture has a lot to do with how we operate. But how difficult is it to measure?
Human Capital
The Active Share: What’s Culture Got to Do With It?
This piece is approved to use with clients.
As it turns out, culture has a lot to do with how we operate. But how difficult is it to measure? In this episode of The Active Share, Hugo sits down with Dr. Tom Reader, an associate professor of organizational psychology at the London School of Economics, to discuss the broad role culture plays in all kinds of organizations; why great cultures are the defining feature of good companies; and how engaging with diverse perspectives can help foster meaningful cultural growth and innovation.
Human Capital
Podcast 33: Diverse Thought, Endless Possibilities
This piece is approved to use with clients.
When a society embraces cognitive diversity, powerful outcomes can result. In this episode of The Active Share, Hugo sits down with Matthew Syed, a best-selling author, highly acclaimed speaker, and award-winning journalist, to discuss what it means to think in complex ways; the implications of moving away from group think; and how investors can benefit from diverse cultures and voices.
Human Capital
The Active Share Podcast Episode #30: Investing in People
This piece is approved to use with clients.
In this wide-ranging discussion, Aoifinn explains how the Russia-Ukraine conflict could change how we think about ESG, whether we’re in a new investing regime, and what she’s learned from podcasting.
Fixed Income Insights
Views on the Dynamic Post-Pandemic Trading Environment
This piece is approved to use with clients.
Our global fixed income trading team provides valuable insights that inform the positioning in our fixed income portfolios.
Fixed Income Insights
Why the Eurozone Will Not Mirror China’s Post-COVID Recovery
This piece is approved to use with clients.
The eurozone's post-COVID recovery is set to be slower and more painful than China's.